

Features of the course of measles in children in modern conditions

Angelina Alievna Karakotova¹, Malika Islamovna Batdyeva², Sarkis Garekinovich Petrosyan³, Daniil Gennadievich Mikhalev⁴, Danila Sergeevich Safronov³, Alina Igorevna Baturina⁵, Danila Andreevich Nekrasov⁶, Vladislava Sergeevna Kurakina^{7*}

¹Faculty of Pediatrics, Medical Institute, North Caucasus State Academy, Cherkessk, Republic of Karachay-Cherkessia, Russia. ²Faculty of Medicine, Medical Institute, North Caucasus State Academy, Cherkessk, Republic of Karachay-Cherkessia, Russia. ³Faculty of Medicine, North Ossetian State Medical Academy, Vladikavkaz, Republic of North Ossetia-Alania, Russia. ⁴Faculty of Pediatrics, Stavropol State Medical University, Stavropol, Russia. ⁵Faculty of Medicine and Prevention, Rostov State Medical University, Rostov-on-Don, Russia. ⁶Faculty of Medicine, Kursk State Medical University, Kursk, Russia. ⁷Institute of Clinical Medicine named after N.V. Sklifosovsky, First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia.

Correspondence: Vladislava Sergeevna Kurakina, Institute of Clinical Medicine named after N.V. Sklifosovsky, First Moscow State Medical University named after I.M. Sechenov, Moscow, Russia. publab@bk.ru

Received: 27 March 2025; **Revised:** 23 May 2025; **Accepted:** 01 June 2025

ABSTRACT

The article presents the results of a study of the current features of measles in children. The analysis of clinical manifestations, laboratory parameters, and the frequency of complications in vaccinated and unvaccinated patients was carried out. It has been revealed that measles remains highly contagious among the unvaccinated population, while the disease is milder in vaccinated patients. The incubation period averages 10.3 ± 1.4 days. The most common clinical symptoms are fever (98.6%), cough (89.2%), rhinitis (85.1%), and exanthema (94.6%). Laboratory tests revealed characteristic changes, including leukopenia ($3.8 \pm 1.2 \times 10^9/l$), lymphocytosis ($42.5 \pm 7.8\%$), and increased ESR (18.4 ± 6.3 mm/h). Complications such as pneumonia (12.8%) and otitis media (4.7%) mainly develop in unvaccinated patients. The study highlights the importance of vaccine prophylaxis to reduce the severity of the disease and the frequency of complications. The results can be used to optimize the therapeutic and diagnostic process and develop preventive measures.

Keywords: Measles, Vaccination, Clinical manifestations, Laboratory parameters, Complications, Collective immunity

Introduction

Measles is one of the most highly contagious viral infections in the history of mankind [1]. The first documentary evidence of this disease dates back to the 4th century AD, when the ancient Roman physician Aetius first described the characteristic clinical picture of the disease [2]. A significant breakthrough in

understanding the nature of measles occurred at the beginning of the 20th century, when in 1911 D. Andersen and D. Goldberg scientifically substantiated the viral etiology of the disease [3, 4]. The most important stage in the study of measles was the isolation of the pathogen in 1954, carried out by Thomas Peebles and John Enders [5].

The history of mass vaccination against measles began in the middle of the 20th century, when, after the creation of the first vaccine in 1963, the gradual implementation of immunization programs began in various countries of the world [6, 7]. The Soviet Union was one of the first countries to introduce routine measles vaccinations into the national preventive vaccination calendar [8]. In 1968, a single vaccination of children aged 15-18 months was introduced, which significantly reduced the incidence in the country [9].

Access this article online

Website: www.japer.in

E-ISSN: 2249-3379

How to cite this article: Karakotova AA, Batdyeva MA, Petrosyan SG, Mikhalev DG, Kudzieva KA, Baturina AI, et al. Features of the course of measles in children in modern conditions. J Adv Pharm Educ Res. 2025;15(3):53-60. <https://doi.org/10.51847/KTYmbHoXaz>

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

In the developed countries of the West, the introduction of measles vaccination occurred in stages. Initially, immunization programs were aimed at the most vulnerable groups of the population, including preschool children and health workers [10, 11]. Gradually, vaccination coverage expanded, which led to a significant reduction in morbidity.

The global measles control strategy received a new impetus in the 1990s, when the World Health Organization initiated large-scale programs to expand access to vaccines in developing countries [12]. This has led to significant progress in reducing the incidence of measles on the African continent and in some regions of Asia [13]. The measles incidence statistics are shown in **Figures 1 and 2**.

In the modern period, there is a tendency to improve vaccination schemes [14]. Most developed countries have switched to double immunization, which provides more

reliable protection against the disease. The first vaccination is usually carried out at the age of 12-15 months, and revaccination is carried out at the age of 6 years [15-17].

The dynamics of measles vaccination coverage demonstrate significant differences between regions of the world. In countries with a developed healthcare system, immunization rates reach 95% or higher, which makes it possible to maintain a low incidence rate [18-20]. In developing countries, these indicators are significantly lower, which creates the prerequisites for periodic outbreaks of the disease [21, 22]. The technological development of vaccine production has also had a significant impact on the effectiveness of immunization programs [23]. The advent of combined medications, including protection against measles, rubella, and mumps, has simplified the vaccination process and increased its effectiveness [24].




Figure 1. Measles incidence statistics in Russia




Figure 2. Global measles incidence statistics for 2023

An important stage in the development of vaccine prevention was the creation of an immunization monitoring system and

evaluation of its effectiveness. Modern approaches include not only accounting for the number of vaccinated individuals but

also regular analysis of antibody levels in the population, which allows timely adjustment of immunization programs [25-29]. In recent decades, special attention has been paid to maintaining a high level of collective immunity. This is due to the fact that a decrease in vaccination coverage can lead to a sharp increase in morbidity, as was observed in some countries in the early 2010s [30, 31]. International cooperation in measles vaccine prevention continues to develop, which is reflected in joint programs to strengthen immunization systems, develop new vaccines, and improve disease control strategies [31-33]. Special attention is paid to the availability of vaccines in countries with limited resources and to raising public awareness of the importance of immunization [34].

In modern conditions, the epidemiological situation of measles is characterized by a certain instability. There is a wave-like course of morbidity associated with various factors, including migration processes, changes in vaccination coverage, and the emergence of new strains of the pathogen [35-37]. Particular attention is drawn to the tendency to change the clinical picture of the disease, which requires constant monitoring and adaptation of approaches to diagnosis and treatment [38, 39]. In modern epidemiological conditions, the clinical picture of measles has undergone certain changes compared to the pre-vaccination period. The dynamics of the clinical manifestations of the disease demonstrate a tendency to modify the main symptoms and change the severity of the disease [40-42].

The incubation period of measles currently tends to shorten, which is associated with the peculiarities of the body's modern immune response [43]. Early manifestations of the disease are often blurred, which makes timely diagnosis difficult and can lead to late isolation of patients [44].

The catarrhal period in vaccinated patients often proceeds more mildly, with less pronounced symptoms of intoxication [45, 46]. Cough and rhinitis may be mild or absent, which creates certain difficulties in differential diagnosis [47].

The rash period has also changed. Filatov-Koplik spots may be less pronounced or absent, making early diagnosis difficult. The stages of rashes are sometimes disrupted, and the characteristic rash may have atypical localization [48-51].

The severity of the disease in modern conditions varies depending on the patient's immune status and the presence of concomitant diseases. Measles is more severe in unvaccinated children and people with immunodeficiency conditions, with a higher probability of complications [52, 53]. Complications of measles are less common in modern conditions, but their spectrum has changed. Secondary bacterial infections come to the fore, especially in patients with weakened immune systems [54, 55]. There is a tendency to increase the incidence of pneumonia and otitis media [56, 57].

Atypical forms of measles have become more common. Vaccinated patients may have a mitigated form of the disease with a mild course and the absence of a typical rash [58, 59]. Individuals with immunodeficiency conditions may develop a malignant form of measles with a severe course and high mortality [60, 61].

Laboratory diagnostics of measles in modern conditions has undergone significant changes. The widespread introduction of serological research methods has made it possible to increase the accuracy of diagnosis and identify atypical forms of the disease [62, 63].

The duration of the infection period in modern conditions may vary depending on the form of the disease and the state of the patient's immune system. There is a tendency for the earlier appearance of viral particles in the patient's biological fluids [64, 65]. Susceptibility to infection remains high, especially among unvaccinated individuals. However, the disease is much easier in vaccinated patients, which indicates the high effectiveness of existing vaccines [66, 67]. The prognosis of the disease in modern conditions is generally favorable, provided timely diagnosis and adequate treatment. However, in patients with concomitant diseases and immunodeficiency conditions, the risk of complications remains high.

The relevance of studying the features of the course of measles in modern conditions is due to the need to improve existing strategies for the prevention and treatment of this disease. The study of modern aspects of the pathogenesis, clinical manifestations, and outcomes of measles makes it possible to optimize approaches to patient management and develop more effective measures to control the spread of infection. Of particular importance is the analysis of the transformation of clinical manifestations of measles in the era of mass immunization. Current trends demonstrate both positive changes in the form of a decrease in the severity of the disease and the frequency of complications, as well as the emergence of new challenges associated with changes in the epidemiological situation and the appearance of atypical forms of the disease.

Materials and Methods

The clinical base of the study is represented by children's district polyclinics in the cities of Karachayevsk, Cherkessk, and Vladikavkaz. In the period from 2018 to 2024, a comprehensive examination of 148 children with a clinically confirmed diagnosis of measles was conducted (Table 1).

Table 1. Characteristics of the study group

Indicator	Value
Total number of patients	148 children
Age range	from 1 year to 14 years old
Average age	5.6 ± 1.2 years
Boys	84 (56,8%)
Girls	64 (43,2%)
Vaccinated	42 (28,4%)
Unvaccinated	106 (71,6%)
The season of morbidity	mainly the winter-spring period

The seasonality of the disease demonstrated a typical pattern for measles with a predominance of cases in the winter-spring

period, which corresponds to the well-known epidemiological data on the spread of this infection [68].

Clinical research methods included an integrated approach to the examination of each patient. Special attention was paid to collecting a detailed medical history of the disease, including an epidemiological history, which made it possible to identify possible sources of infection and ways of its transmission. A thorough physical examination was performed with an assessment of the general condition, thermometry, condition of the skin and mucous membranes, and examination of the lymphatic system.

Laboratory diagnostics were carried out using modern research methods. The examination program included:

- A general clinical blood test with a detailed leukocyte formula made it possible to assess the degree of the inflammatory reaction and the nature of changes in peripheral blood.
- Serological studies for the presence of specific IgM and IgG class antibodies to the measles virus were a key method of confirming the diagnosis.
- PCR diagnostics were performed to detect measles virus RNA in biological materials, which made it possible to confirm the diagnosis in the early stages of the disease.
- A biochemical blood test included an assessment of the functional state of the liver and determination of the level of C-reactive protein.
- A general urinalysis was performed to assess the general condition of the body and identify possible complications.
- Instrumental diagnostics included X-ray examination of the chest organs in case of suspected pneumonia and other complications. If necessary, an ultrasound examination of the abdominal organs was performed.

Statistical data processing was carried out using modern methods of mathematical statistics. The reliability of the differences was assessed using Student's criterion. The differences at $p < 0.05$ were considered statistically significant.

All studies were conducted in compliance with the ethical standards and principles of the Helsinki Declaration. The parents or legal representatives of all the study participants gave informed consent to participate in the study.

Results and Discussion

The clinical picture of the disease in the examined patients had several characteristic features. The incubation period averaged 10.5 ± 2.1 days, with a range from 7 to 14 days. In 15% of patients, the incubation period was shortened to 7-9 days, which may be due to the peculiarities of the modern immune response. The dynamics of clinical manifestations are represented by the following features (**Table 2**):

Table 2. Frequency of clinical symptoms

Symptoms	Frequency of occurrence (%)
Fever	98.6
Cough	89.2
Rhinitis	85.1
Conjunctivitis	76.3
Filatov-Koplik Spots	68.9
Exanthema	94.6

The period of catarrhal events in the majority of patients (78.4%) lasted 3-4 days. Prolongation of the prodromal period to 5-6 days was noted in 21.6% of patients.

Features of the rash in the examined patients: the onset of rashes on the 4th-5th day after the onset of the disease; the stage of rash appearance was disrupted in 32.5% of patients; discharge elements were observed in 18.9% of patients; atypical forms of rash were observed in 12.2% of patients. The severity of the disease is shown in **Table 3**. Complications developed in 28 (19%) patients. The structure of complications is shown in **Table 4**. Laboratory parameters of blood and urine are presented in **Table 5**.

Table 3. Distribution by severity of the current

Form of the disease	Vaccinated (%)	Unvaccinated (%)
Easy	84.4	25.8
Medium-heavy	13.6	62.3
Heavy	2.0	11.9

Table 4. Complication rate

Complication	Frequency of occurrence (%)
Pneumonia	12.8
Otitis media	4.7
Stomatitis	1.4
Encephalitis	0.7

Table 5. Laboratory parameters of blood and urine ($M \pm SD$)

Indicator	Measles patients	Standard
Indicators of the general blood test		
White blood cells, $\times 10^9/l$	$4,2 \pm 1,1$	4,0-9,0
Lymphocytes, %	$48,6 \pm 7,2$	19-37
Monocytes, %	$9,4 \pm 2,1$	3-11
ESR, mm/hr	$18,5 \pm 6,3$	2-10
Biochemical parameters of blood		
Total protein, g/l	$68,4 \pm 5,2$	65-85
ALT, Unit/l	$42,3 \pm 15,6$	up to 41
AST, Unit/l	$38,5 \pm 12,4$	up to 38
C-reactive protein, mg/l	$12,4 \pm 4,5$	up to 5
Indicators of general urinalysis		

Relative density	1012 ± 0,05	1005-1025
Protein, g/l	0,03 ± 0,01	no
White blood cells, in the field of vision	3-4	0-2

Laboratory parameters showed the following changes:

- Leukopenia at the onset of the disease in 76.3% of patients
- Lymphocytosis was observed in 68.9% of patients
- An increase in ESR was observed in 82.5% of patients
- Mild thrombocytopenia in 15.6% of patients

Serological parameters confirmed the diagnosis in all examined patients. Vaccinated children had a higher titer of IgG class antibodies, which correlated with a milder course of the disease. The data obtained indicate that measles retains its characteristic features in modern conditions. There is a tendency to decrease the severity of the disease in vaccinated patients.

Changes in blood tests reflect a typical body reaction to a viral infection: moderate leukopenia, lymphocytosis, increased ESR, and a slight increase in liver enzymes.

The dynamics of recovery were characterized by the following features: a decrease in temperature on an average of 7-9 days of illness, the disappearance of the rash by 10-14 days, and normalization of laboratory parameters by 3-4 weeks of illness.

A comparative analysis of the course of the disease in vaccinated and unvaccinated patients showed statistically significant differences:

- In vaccinated patients, the disease was milder
- The duration of the fever period was shorter by 2-3 days
- The complication rate was 2.5 times lower

Thus, the data obtained indicate that the measles virus remains highly contagious. There is a tendency to a milder course of the disease in vaccinated patients, which confirms the effectiveness of existing vaccines. It should be noted that severe forms of the disease were more common in unvaccinated patients; the seasonality of the disease remains pronounced; complications mainly developed in unvaccinated patients; modern diagnostic methods ensure high accuracy of diagnosis verification.

Conclusion

The conducted research allowed us to obtain significant data on the current features of measles in children and the effectiveness of vaccine prophylaxis. The main results of the study demonstrate that measles remains relevant as an infectious disease that requires the close attention of the medical community. Despite the availability of an effective vaccine, the disease continues to be reported, mainly among the unvaccinated population. The clinical picture of measles in modern conditions is characterized by a typical course with the

presence of all stages of the disease. However, vaccinated patients have a milder course of the disease with fewer symptoms of intoxication and a lower incidence of complications.

Laboratory parameters confirm the viral nature of the disease and allow monitoring of the dynamics of the pathological process. Characteristic changes are leukopenia, lymphocytosis, and increased ESR.

Complications of measles remain a serious problem, especially among unvaccinated patients. The most common complications are pneumonia and otitis media, which highlights the importance of timely vaccination.

Acknowledgments: None

Conflict of interest: None

Financial support: None

Ethics statement: All studies were conducted in compliance with the ethical standards and principles of the Helsinki Declaration. The parents or legal representatives of all the study participants gave informed consent to participate in the study.

References

1. Dunn JJ, Baldanti F, Puchhammer E, Panning M, Perez O, Harvala H, et al. Measles is back - considerations for laboratory diagnosis. *J Clin Virol.* 2020;128:104430. doi:10.1016/j.jcv.2020.104430
2. Berche P. History of measles. *Presse Med.* 2022;51(3):104149. doi:10.1016/j.lpm.2022.104149
3. Cant S, Shanks GD, Keeling MJ, Penman BS. Extreme mortality during a historical measles outbreak on Rotuma is consistent with measles immunosuppression. *Epidemiol Infect.* 2024;152:e85. doi:10.1017/S095026882400075X
4. Kurpas D, Stefanicka-Wojtas D, Soll-Morka A, Lomper K, Uchmanowicz B, Blahova B, et al. Vaccine hesitancy and immunization patterns in central and eastern Europe: sociocultural, economic, political, and digital influences across seven countries. *Risk Manag Healthc Policy.* 2025;18:1911-34. doi:10.2147/RMHP.S519479
5. Enders JF. Vaccination against measles. *Aust J Exp Biol Med Sci.* 1963;41:SUPPL467-89. doi:10.1038/icb.1963.67
6. Barteska P, Dobkowitz S, Olkkola M, Rieser M. Mass vaccination and educational attainment: evidence from the 1967-68 measles eradication campaign. *J Health Econ.* 2023;92:102828. doi:10.1016/j.jhealeco.2023.102828
7. Vaux S, Fonteneau L, Péfau M, Venier AG, Gautier A, Altrach SS, et al. Acceptability of mandatory vaccination against influenza, measles, pertussis and varicella by workers in healthcare facilities: a national cross-sectional

- study, France, 2019. *Arch Public Health*. 2023;81(1):51. doi:10.1186/s13690-023-01069-4
8. Kantner AC, van Wees SH, Olsson EMG, Ziaei S. Factors associated with measles vaccination status in children under the age of three years in a post-soviet context: a cross-sectional study using the DHS VII in Armenia. *BMC Public Health*. 2021;21(1):552. doi:10.1186/s12889-021-10583-5
9. Bellini WJ, Rota JS, Rota PA. Virology of the measles virus. *J Infect Dis*. 1994;170 Suppl 1:S15-23. doi:10.1093/infdis/170.supplement_1.s15
10. Fiebelkorn AP, Seward JF, Orenstein WA. A global perspective of vaccination of healthcare personnel against measles: systematic review. *Vaccine*. 2014;32(38):4823-39. doi:10.1016/j.vaccine.2013.11.005
11. Lee JS, Jeong O, Yang H. Screening and vaccination against measles and varicella among health care workers: a cost-effectiveness analysis. *Asia Pac J Public Health*. 2021;33(5):508-15. doi:10.1177/10105395211026468
12. Kim C, Yin Z, Kamdar N, Stidham R. Vaccination against measles, mumps, rubella and incident inflammatory bowel disease in a national cohort of privately insured children. *Inflamm Bowel Dis*. 2023;29(3):430-6. doi:10.1093/ibd/izac176
13. Gao Y, Kc A, Chen C, Huang Y, Wang Y, Zou S, et al. Inequality in measles vaccination coverage in the "big six" countries of the WHO South-East Asia region. *Hum Vaccin Immunother*. 2020;16(7):1485-97. doi:10.1080/21645515.2020.1736450
14. Baroutsou V, Wymann M, Zens K, Sinniger P, Fehr J, Lang P. National and regional variations in timely adherence to the recommended measles vaccination scheme in 2-year-olds in Switzerland, 2005-2019. *Vaccine*. 2022;40(22):3055-63. doi:10.1016/j.vaccine.2022.04.008
15. Jean Baptiste AE, Masresha B, Wagai J, Luce R, Oteri J, Dieng B, et al. Trends in measles incidence and measles vaccination coverage in Nigeria, 2008-2018. *Vaccine*. 2021;39 Suppl 3:C89-C95. doi:10.1016/j.vaccine.2021.03.095
16. Benn CS, Aaby P. Measles vaccination and reduced child mortality: prevention of immune amnesia or beneficial non-specific effects of measles vaccine? *J Infect*. 2023;87(4):295-304. doi:10.1016/j.jinf.2023.07.010
17. Stein-Zamir C, Shooob H, Abramson D. Measles clinical presentation, hospitalization, and vaccination status among children in a community-wide outbreak. *Vaccine*. 2023;41(17):2764-8. doi:10.1016/j.vaccine.2023.03.043
18. Jeimy S, Hildebrandt KJ, Vohra-Miller S. Measles vaccination. *CMAJ*. 2024;196(15):E525. doi:10.1503/cmaj.240371
19. Lang P, Zens KD, Bally B, Meier C, Martin B, Fehr J. Evaluation of a measles vaccination campaign at the universities in the city of Zurich, 2019. *Public Health*. 2021;195:51-3. doi:10.1016/j.puhe.2021.03.023
20. Sindoni A, Baccolini V, Adamo G, Massimi A, Migliara G, De Vito C, et al. Effect of the mandatory vaccination law on measles and rubella incidence and vaccination coverage in Italy (2013-2019). *Hum Vaccin Immunother*. 2022;18(1):1950505. doi:10.1080/21645515.2021.1950505
21. Alemu TG, Tamir TT, Workneh BS, Mekonen EG, Ali MS, Zegeye AF, et al. Coverage and determinants of second-dose measles vaccination among under-five children in East African countries: a systematic review and meta-analysis. *Front Public Health*. 2024;12:1359572. doi:10.3389/fpubh.2024.1359572
22. Auzenberg M, Fu H, Abbas K, Procter SR, Cutts FT, Jit M. Health effects of routine measles vaccination and supplementary immunisation activities in 14 high-burden countries: a Dynamic Measles Immunization Calculation Engine (DynaMICE) modelling study. *Lancet Glob Health*. 2023;11(8):e1194-204. doi:10.1016/S2214-109X(23)00220-6
23. Ly H. Measles disease outbreaks and vaccination impacting global public health. *J Med Virol*. 2024;96(4):e29593. doi:10.1002/jmv.29593
24. Sadovoy VV, Selimov M, Shchedrina T, Nagdalian AA. Nutritional supplement for the control of diabetes. *J Excip Food Chem*. 2017;8352017:1843.
25. Azan L, Chuecos-Escalante S, Marte AP, Bhagi N. Measles in the modern era: a review. *Pediatr Ann*. 2024;53(9):e345-50. doi:10.3928/19382359-20240722-01
26. Parums DV. A review of the resurgence of measles, a vaccine-preventable disease, as current concerns contrast with past hopes for measles elimination. *Med Sci Monit*. 2024;30:e944436. doi:10.12659/MSM.944436
27. Cherry JD. Ongoing measles in the developed and developing world. *J Pediatric Infect Dis Soc*. 2024;13(4):233-6. doi:10.1093/jpids/piae018
28. Watanabe S, Masamura N, Satoh S, Hirao T. Evaluating the Effectiveness of DNA barcoding for insect identification: a comprehensive review. *Entomol Lett*. 2024;4(2):34-41. doi:10.51847/ZVNniNFsOR
29. Patil RD. Structural insights into the alimentary canal of *deudorix isocrates* (Fab.) Larvae (Lepidoptera: Lycaenidae). *Entomol Lett*. 2022;2(1):28-36. doi:10.51847/PoTmk4aq6W
30. Vojtek I, Larson H, Plotkin S, Van Damme P. Evolving measles status and immunization policy development in six European countries. *Hum Vaccin Immunother*. 2022;18(1):2031776. doi:10.1080/21645515.2022.2031776
31. Healy A. Measles: increasing vaccine uptake is vital in preventing outbreaks. *BMJ*. 2024;384:q402. doi:10.1136/bmj.q402
32. Dongmo LF, Tamesse JL. Population trends of *hilda cameroonensis tamesse & dongmo* (Tettigometridae), a pest of *vernonia amygdalina delile* in Yaoundé, Cameroon.

- Int J Vet Res Allied Sci. 2023;3(1):1-10. doi:10.51847/CurzkzD60G
33. Fiodorova OA, Sivkova EI, Nikonov AA. Safeguarding beef cattle from gnats and gadflies in the southern tyumen region. *Int J Vet Res Allied Sci.* 2022;2(2):8-13. doi:10.51847/iVXOeXmSNZ
 34. Peter OJ. Modelling measles transmission dynamics and the impact of control strategies on outbreak management. *J Biol Dyn.* 2025;19(1):2479448. doi:10.1080/17513758.2025.2479448
 35. Akash S, Islam MR, Rahman MM. Measles virus outbreak: a new concern for public health, pathogenesis, diagnosis, genomic features, and treatment criteria - correspondence. *Int J Surg.* 2023;109(2):201-3. doi:10.1097/JS9.0000000000000238
 36. Popofsky S, Romero JR. Measles: an ongoing threat. *Pediatr Ann.* 2025;54(5):e167-73. doi:10.3928/19382359-20250307-03
 37. Marian M, Shah R, Gashi B, Zhang S, Bhavnani K, Wartack S, et al. The role of synovial fluid morphology in joint lubrication and function. *Int J Vet Res Allied Sci.* 2024;4(2):1-4. doi:10.51847/WXAMJiBFbr
 38. Dipalma G, Inchingolo AD, Fiore A, Balestriere L, Nardelli P, Casamassima L, et al. Comparative effects of fixed and clear aligner therapy on oral microbiome dynamics. *Asian J Periodontics Orthod.* 2022;2:33-41. doi:10.51847/mK28wdKCIX
 39. Klassen-Fischer MK, Nelson AM, Neafie RC, Neafie FA, Auerbach A, Baker TP, et al. The reemergence of measles. *Am J Clin Pathol.* 2023;159(1):81-8. doi:10.1093/ajcp/aqac124
 40. Tanaka H, Takahashi Y, Matsumoto S, Matsuyama M, Nakayama K, Kodaira H, et al. Shorter incubation period in symptomatic measles patients who had no history of measles vaccination. *Vaccine.* 2025;45:126652. doi:10.1016/j.vaccine.2024.126652
 41. Pisano M, Sangiovanni G, Frucci E, Scorziello M, Benedetto GD, Iandolo A. Assessing the reliability of electronic apex locators in different apical foramen configurations. *Asian J Periodontics Orthod.* 2023;3:1-5. doi:10.51847/qOUk0OkkRZ
 42. Bolay Ş, Öztürk E, Tuncel B, Ertan A. Studying fracture strength of root-treated and reconstructed teeth with two types of post and core. *Ann J Dent Med Assist.* 2024;4(2):1-6. doi:10.51847/i57dzmzc2A
 43. Naureckas Li C, Kaplan SL, Edwards KM, Marshall GS, Parker S, Mary Healy C. What's old is new again: measles. *Pediatrics.* 2025;155(6):e2025071332. doi:10.1542/peds.2025-071332
 44. Pelevin SI, Taubaev BD, Baklanov IS. Problem of technogenic society dynamics under the conditions of contemporaneity. *Int J Civ Eng Technol.* 2018;9(11):2437-43.
 45. Chen W, Du M, Deng J, Liu M, Liu J. Global, regional, and national trends of measles burden and its vaccination coverage among children under 5 years old: an updated systematic analysis from the global burden of disease study 2021. *Int J Infect Dis.* 2025;156:107908. doi:10.1016/j.ijid.2025.107908
 46. Bulusu A, Cleary SD. Comparison of dental caries in autistic children with healthy children. *Ann J Dent Med Assist.* 2023;3(2):14-9. doi:10.51847/wa2pZXE4RJ
 47. Barnekow D, Neucom D, Tout W, Williams D, Thomas MJ, Schlebusch S, et al. Measles secondary vaccine failure in a childcare setting: an outbreak report. *Commun Dis Intell (2018).* 2024;48. doi:10.33321/cdi.2024.48.61
 48. Steichen O, Dautheville S. Koplik spots in early measles. *CMAJ.* 2009;180(5):583. doi:10.1503/cmaj.080724
 49. Washam MC, Leber AL, Oyeniran SJ, Everhart K, Wang H. Shedding of measles vaccine RNA in children after receiving measles, mumps and rubella vaccination. *J Clin Virol.* 2024;173:105696. doi:10.1016/j.jcv.2024.105696
 50. Matysiak-Klose D, Mankertz A, Holzmann H. The epidemiology and diagnosis of measles—special aspects relating to low incidence. *Dtsch Arztebl Int.* 2024;121(26):875-81. doi:10.3238/arztebl.m2024.0211
 51. Malcangi G, Patano A, Trilli I, Piras F, Ciocia AM, Inchingolo AD, et al. A systematic review of the role of soft tissue lasers in enhancing esthetic dental procedures. *Int J Dent Res Allied Sci.* 2023;3(2):1-8. doi:10.51847/DWXltUS9Lp
 52. AlHussain BS, AlFayez AA, AlDuhaymi AA, AlMulhim EA, Assiri MY, Ansari SH. Impact of different antibacterial substances in dental composite materials: a comprehensive review. *Int J Dent Res Allied Sci.* 2022;2(1):1-7. doi:10.51847/jg2xu2PbJK
 53. Cholewik M, Stępień M, Eksmond M, Piotrowska A, Sokołowska M, Bieńkowski C, et al. Measles complications in pediatric patients in Poland. *Pediatr Infect Dis J.* 2023;42(11):e430-1. doi:10.1097/INF.00000000000004070
 54. Fappani C, Gori M, Canuti M, Terraneo M, Colzani D, Tanzi E, et al. Breakthrough infections: a challenge towards measles elimination? *Microorganisms.* 2022;10(8):1567. doi:10.3390/microorganisms10081567
 55. Manea ASB, Alqahtani AD, Alhazzaa AK, Albalawi AO, Alotaibi AK, Alanazi TF. Systematic review of the microbiological impact of sodium hypochlorite concentrations in endodontic treatment. *Int J Dent Res Allied Sci.* 2024;4(2):9-15. doi:10.51847/PH80PpWOX7
 56. Shaheen RS, Alsaffan AD, Al-Dusari RS, Helmi RN, Baseer MA. Self-reported oral hygiene and gum health among dental and medical students, dentists, and physicians in Saudi Arabia. *Turk J Public Health Dent.* 2023;3(1):9-16. doi:10.51847/SZCGti8IFn
 57. Krow-Lucal E, Marin M, Shepersky L, Bahta L, Locher J, Dooling K. Measles, mumps, rubella vaccine (PRIORIX): recommendations of the advisory committee on immunization practices - United States, 2022. *MMWR*

- Morb Mortal Wkly Rep. 2022;71(46):1465-70. doi:10.15585/mmwr.mm7146a1
58. Dey PK, Ghosh A. Atypical presentation of fulminating subacute sclerosing panencephalitis: a case series. *Neuropediatrics*. 2021;52(1):52-5. doi:10.1055/s-0040-1715623
 59. Ravoori S, Sekhar PR, Pachava S, Pavani NPM, Shaik PS, Ramanarayana B. Perceived stress and depression among oral cancer patients - a hospital based cross-sectional study. *Turk J Public Health Dent*. 2024;4(1):1-5. doi:10.51847/FoK9xAl1JW
 60. Fernandes AL, Malik JB, Ansari SR, Murali S, Thirupathii J. Saudi dentists' knowledge and approaches to managing tooth wear: a cross-sectional survey-based analysis. *Turk J Public Health Dent*. 2022;2(2):1-12. doi:10.51847/p7ulFD4XZm
 61. Yu B, Kline C, Hoare O, Jung J, Knowles T, Ranavaya A, et al. Measles oncolytic virus as an immunotherapy for recurrent/refractory pediatric medulloblastoma and atypical teratoid rhabdoid tumor: results from PNOC005. *Clin Cancer Res*. 2025. doi:10.1158/1078-0432.CCR-24-3721
 62. Paul L, Jain T, Agarwal M, Singh S. Subacute sclerosing panencephalitis manifesting as bell's palsy and bilateral macular necrotizing retinitis: an atypical presenting feature. *J Ophthalmic Inflamm Infect*. 2021;11(1):2. doi:10.1186/s12348-020-00223-1
 63. Graefen B, Hasanli S, Fazal N. Behind the white coat: the prevalence of burnout among obstetrics and gynecology residents in Azerbaijan. *Bull Pioneer Res Med Clin Sci*. 2023;2(2):1-7. doi:10.51847/vIIhM1UG2l
 64. Dhanasekar P, Rajayyan JS, Veerabadiran Y, Kumar KS, Kumar KS, Chinnadurai N. Evaluation of alum and purification process of water by coagulation method. *Bull Pioneer Res Med Clin Sci*. 2022;1(2):1-6. doi:10.51847/R8GyfOmMDh
 65. Chettouh H, Haddad K, Mahieddine N, Mekki A, Zeroual Z, Berrou Z, et al. Subacute sclerosing panencephalitis: Disease profile in early childhood. *Arch Pediatr*. 2025;32(3):175-83. doi:10.1016/j.arcped.2024.11.010
 66. Moss WJ, Griffin DE. What's going on with measles? *J Virol*. 2024;98(8):e0075824. doi:10.1128/jvi.00758-24
 67. Makhoahle P, Gaseitsiwe T. Efficacy of disinfectants on common laboratory surface microorganisms at R.S mangaliso hospital, NHLS laboratory, South Africa. *Bull Pioneer Res Med Clin Sci*. 2022;1(1):1-12. doi:10.51847/d5bXpXAtcl
 68. Davila-Payan CS, Hill A, Kayembe L, Alexander JP, Lynch M, Pallas SW. Analysis of the yearly transition function in measles disease modeling. *Stat Med*. 2024;43(3):435-51. doi:10.1002/sim 9951